

## The TIDieR (Template for Intervention Description and Replication) Checklist\*:

Information to include when describing an intervention and the location of the information

Item number	Item	Where located **	
		Primary paper (page or appendix number)	Other † (details)
1.	<p><b>BRIEF NAME</b> Provide the name or a phrase that describes the intervention.</p>	Page 22_____	_____
2.	<p><b>WHY</b> Describe any rationale, theory, or goal of the elements essential to the intervention.</p>	Page 7-8_____	_____
3.	<p><b>WHAT</b> Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g. online appendix, URL).</p>	Page 19-21_____	_____
4.	<p>Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities.</p>	_____	<p>Page 11-12 in protocol (Hølmkjær P, Holm A, Overbeck G, Rozing MP. A cluster-randomized trial of a complex intervention to encourage deprescribing antidepressants in nursing home residents with dementia: a study protocol. <i>Trials</i>. 2022 May 16;23(1):410. doi: 10.1186/s13063-022-06368-9. PMID: 35578351; PMCID: PMC9109433.)_____</p>

<b>WHO PROVIDED</b>			
5.	For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given.	_____N/A_____	Page 11 in protocol (Hølmkjær P, Holm A, Overbeck G, Rozing MP. A cluster-randomized trial of a complex intervention to encourage deprescribing antidepressants in nursing home residents with dementia: a study protocol. <i>Trials</i> . 2022 May 16;23(1):410. doi: 10.1186/s13063-022-06368-9. PMID: 35578351; PMCID: PMC9109433.)_____
<b>HOW</b>			
6.	Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group.	_____N/A_____	Page 11 in protocol (Hølmkjær P, Holm A, Overbeck G, Rozing MP. A cluster-randomized trial of a complex intervention to encourage deprescribing antidepressants in nursing home residents with dementia: a study protocol. <i>Trials</i> . 2022 May 16;23(1):410. doi: 10.1186/s13063-022-06368-9. PMID: 35578351; PMCID: PMC9109433.)_____
<b>WHERE</b>			
7.	Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.	Page 21_____	_____
<b>WHEN and HOW MUCH</b>			
8.	Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose.	_____N/A_____	_____

**TAILORING**

9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how.

\_\_\_\_\_ N/A \_\_\_\_\_

**MODIFICATIONS**

10.† If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).

Page  
21 \_\_\_\_\_

**HOW WELL**

11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.

\_\_\_\_\_

Page 14 in protocol (Hølmkjær P, Holm A, Overbeck G, Rozing MP. A cluster-randomized trial of a complex intervention to encourage deprescribing antidepressants in nursing home residents with dementia: a study protocol. *Trials*. 2022 May 16;23(1):410. doi: 10.1186/s13063-022-06368-9. PMID: 35578351; PMCID: PMC9109433.) \_\_\_\_\_

12.‡ If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.

\_\_\_\_\_

\*\* **Authors** - use N/A if an item is not applicable for the intervention being described. **Reviewers** – use ‘?’ if information about the element is not reported/not sufficiently reported.

† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL).

‡ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete.

\* We strongly recommend using this checklist in conjunction with the TIDieR guide (see *BMJ* 2014;348:g1687) which contains an explanation and elaboration for each item.

\* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a **randomised trial** is being reported, the TIDieR checklist should be used in conjunction with the CONSORT statement (see [www.consort-statement.org](http://www.consort-statement.org)) as an extension of **Item 5 of the CONSORT 2010 Statement**. When a **clinical trial protocol** is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of **Item 11 of the SPIRIT 2013 TIDieR checklist**

**Statement** (see [www.spirit-statement.org](http://www.spirit-statement.org)). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see [www.equator-network.org](http://www.equator-network.org)).